Skip to Content

Generic Minivelle Availability

Minivelle is a brand name of estradiol, approved by the FDA in the following formulation(s):

MINIVELLE (estradiol - film, extended release;transdermal)

  • Manufacturer: NOVEN
    Approval date: October 29, 2012
    Strength(s): 0.0375MG/24HR, 0.05MG/24HR, 0.075MG/24HR, 0.1MG/24HR [RLD]
  • Manufacturer: NOVEN
    Approval date: September 23, 2014
    Strength(s): 0.025MG/24HR

Has a generic version of Minivelle been approved?

No. There is currently no therapeutically equivalent version of Minivelle available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Minivelle. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patch
    Patent 6,841,716
    Issued: January 11, 2005
    Inventor(s): Tsutsumi; Nobuo
    Assignee(s): Hisamitsu Pharmaceutical Co., Inc.
    According to the invention, a patch provided with a support 1, an adhesive layer 2 laminated on one side of the support, and a release film 4 attached in a releasable manner to the adhesive layer and having a slit 42 running from one edge to the opposite edge, is characterized in that the shape of the slit in the release film is a wave shape such that, by simply bending the support slightly along the slit while the exposed side of the adhesive layer which has been exposed by peeling off part of the release film along the slit is attached to the attachment site, the edge 44 of the slit of the remaining release film can promptly protrude outward from between the attachment site and the adhesive layer.
    Patent expiration dates:
    • April 27, 2020
      Drug product
  • Transdermal estrogen device and delivery
    Patent 8,231,906
    Issued: July 31, 2012
    Inventor(s): Mantelle; Juan
    Assignee(s): Noven Pharmaceuticals, Inc.
    Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.
    Patent expiration dates:
    • July 4, 2030
      Drug substance
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.